vs
Side-by-side financial comparison of BillionToOne, Inc. (BLLN) and CS Disco, Inc. (LAW). Click either name above to swap in a different company.
BillionToOne, Inc. is the larger business by last-quarter revenue ($83.5M vs $41.9M, roughly 2.0× CS Disco, Inc.). BillionToOne, Inc. runs the higher net margin — 6.8% vs -23.0%, a 29.8% gap on every dollar of revenue. On growth, BillionToOne, Inc. posted the faster year-over-year revenue change (117.4% vs 14.3%).
BillionToOne, Inc. is a life sciences and molecular diagnostics firm developing high-precision genetic testing solutions. Its core offerings include non-invasive prenatal tests, oncology diagnostics, and rare disease screening, serving clinical providers and patients mainly in North America.
CS Disco, Inc. is a leading legal technology provider that develops cloud-based software solutions for legal practitioners. Its core offerings include e-discovery, document review, case management, and legal workflow automation tools, serving law firms, corporate legal teams, and government legal departments primarily in North America.
BLLN vs LAW — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $83.5M | $41.9M |
| Net Profit | $5.7M | $-9.6M |
| Gross Margin | 69.9% | 74.2% |
| Operating Margin | 11.5% | 1.7% |
| Net Margin | 6.8% | -23.0% |
| Revenue YoY | 117.4% | 14.3% |
| Net Profit YoY | 138.3% | 15.6% |
| EPS (diluted) | $0.10 | $-0.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $41.9M | ||
| Q4 25 | — | $41.2M | ||
| Q3 25 | $83.5M | $40.9M | ||
| Q2 25 | — | $38.1M | ||
| Q1 25 | — | $36.7M | ||
| Q4 24 | $45.1M | $37.0M | ||
| Q3 24 | $38.4M | $36.3M | ||
| Q2 24 | — | $36.0M |
| Q1 26 | — | $-9.6M | ||
| Q4 25 | — | $-8.5M | ||
| Q3 25 | $5.7M | $-13.7M | ||
| Q2 25 | — | $-10.8M | ||
| Q1 25 | — | $-11.4M | ||
| Q4 24 | $-11.5M | $-25.2M | ||
| Q3 24 | $-14.9M | $-9.2M | ||
| Q2 24 | — | $-10.8M |
| Q1 26 | — | 74.2% | ||
| Q4 25 | — | 75.1% | ||
| Q3 25 | 69.9% | 75.5% | ||
| Q2 25 | — | 74.6% | ||
| Q1 25 | — | 74.1% | ||
| Q4 24 | 57.1% | 74.2% | ||
| Q3 24 | 52.6% | 73.1% | ||
| Q2 24 | — | 74.2% |
| Q1 26 | — | 1.7% | ||
| Q4 25 | — | -22.4% | ||
| Q3 25 | 11.5% | -35.3% | ||
| Q2 25 | — | -31.0% | ||
| Q1 25 | — | -34.4% | ||
| Q4 24 | 17.0% | -70.6% | ||
| Q3 24 | -32.9% | -30.0% | ||
| Q2 24 | — | -34.4% |
| Q1 26 | — | -23.0% | ||
| Q4 25 | — | -20.7% | ||
| Q3 25 | 6.8% | -33.4% | ||
| Q2 25 | — | -28.4% | ||
| Q1 25 | — | -31.1% | ||
| Q4 24 | -25.5% | -68.1% | ||
| Q3 24 | -38.8% | -25.3% | ||
| Q2 24 | — | -30.1% |
| Q1 26 | — | $-0.15 | ||
| Q4 25 | — | $-0.13 | ||
| Q3 25 | $0.10 | $-0.22 | ||
| Q2 25 | — | $-0.18 | ||
| Q1 25 | — | $-0.19 | ||
| Q4 24 | $-1.13 | $-0.43 | ||
| Q3 24 | $-1.47 | $-0.15 | ||
| Q2 24 | — | $-0.18 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $195.2M | $103.0M |
| Total DebtLower is stronger | $55.0M | — |
| Stockholders' EquityBook value | $-239.5M | $123.9M |
| Total Assets | $327.5M | $162.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $103.0M | ||
| Q4 25 | — | $114.6M | ||
| Q3 25 | $195.2M | $113.5M | ||
| Q2 25 | — | $114.5M | ||
| Q1 25 | — | $118.8M | ||
| Q4 24 | $191.5M | $129.1M | ||
| Q3 24 | — | $126.8M | ||
| Q2 24 | — | $130.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $55.0M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $51.5M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $123.9M | ||
| Q4 25 | — | $128.1M | ||
| Q3 25 | $-239.5M | $130.6M | ||
| Q2 25 | — | $137.9M | ||
| Q1 25 | — | $142.2M | ||
| Q4 24 | $-251.7M | $147.5M | ||
| Q3 24 | $-242.9M | $167.3M | ||
| Q2 24 | — | $170.9M |
| Q1 26 | — | $162.4M | ||
| Q4 25 | — | $173.6M | ||
| Q3 25 | $327.5M | $174.8M | ||
| Q2 25 | — | $164.9M | ||
| Q1 25 | — | $168.0M | ||
| Q4 24 | $302.1M | $180.3M | ||
| Q3 24 | — | $194.4M | ||
| Q2 24 | — | $198.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $13.8M | $-11.7M |
| Free Cash FlowOCF − Capex | $6.5M | — |
| FCF MarginFCF / Revenue | 7.7% | — |
| Capex IntensityCapex / Revenue | 8.8% | — |
| Cash ConversionOCF / Net Profit | 2.42× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $-11.7M | ||
| Q4 25 | — | $762.0K | ||
| Q3 25 | $13.8M | $-979.0K | ||
| Q2 25 | — | $-4.2M | ||
| Q1 25 | — | $-10.5M | ||
| Q4 24 | — | $2.1M | ||
| Q3 24 | — | $-2.9M | ||
| Q2 24 | — | $-650.0K |
| Q1 26 | — | — | ||
| Q4 25 | — | $255.0K | ||
| Q3 25 | $6.5M | $-2.0M | ||
| Q2 25 | — | $-5.2M | ||
| Q1 25 | — | $-11.0M | ||
| Q4 24 | — | $1.5M | ||
| Q3 24 | — | $-3.7M | ||
| Q2 24 | — | $-1.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.6% | ||
| Q3 25 | 7.7% | -5.0% | ||
| Q2 25 | — | -13.6% | ||
| Q1 25 | — | -30.1% | ||
| Q4 24 | — | 4.1% | ||
| Q3 24 | — | -10.3% | ||
| Q2 24 | — | -3.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.2% | ||
| Q3 25 | 8.8% | 2.6% | ||
| Q2 25 | — | 2.5% | ||
| Q1 25 | — | 1.4% | ||
| Q4 24 | — | 1.5% | ||
| Q3 24 | — | 2.4% | ||
| Q2 24 | — | 1.8% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 2.42× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
LAW
Segment breakdown not available.
